Johns Hopkins Arthritis Center

Home / Arthritis News / Are TNF Inhibitors Linked to Increased Risk of Lymphoma?

Are TNF Inhibitors Linked to Increased Risk of Lymphoma?

By


Are TNF Inhibitors linked to increased risk of Lymphoma?

Based on the current safety data, an FDA panel of experts said that additional information is needed in order to determine whether or not there is an increased risk of lymphoma in rheumatoid arthritis (RA) patients receiving TNF inhibitors. No definitive recommendation can be made at this time. Currently, there are 3 TNF inhibitors (Enbrel®, Remicade®, and Humira®) approved for treatment in patients with RA.

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.